Spots Global Cancer Trial Database for alemtuzumab
Every month we try and update this database with for alemtuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | NCT00947388 | Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Bendamustine Hy... Alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | NCT00129753 | Hodgkin's Disea... Lymphoma | Alemtuzumab (Ca... | 18 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia | NCT00162851 | B-CLL | alemtuzumab | 18 Years - 80 Years | Karolinska University Hospital | |
| Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | NCT01392079 | Chronic Lymphoc... | Alemtuzumab | 18 Years - | University of Ulm | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | NCT00278213 | Prolymphocytic ... | alemtuzumab cyclophosphamid... fludarabine pho... mitoxantrone hy... | 18 Years - 70 Years | German CLL Study Group | |
| Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | NCT01191749 | Leukemia | Alemtuzumab | - | M.D. Anderson Cancer Center | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | NCT00836043 | Chronic Lymphoc... | Alemtuzumab (Ma... | 18 Years - | Sanofi | |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia | NCT01982175 | B-cell Chronic ... | Alemtuzumab | 18 Years - 75 Years | Shanghai Zhangjiang Biotechnology Limited Company | |
| Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT01256398 | Acute Lymphobla... Adult B Acute L... | Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) | NCT00930605 | Peripheral T-ce... | CHOP regimen al... Alemtuzumab | 15 Years - 65 Years | King Chulalongkorn Memorial Hospital | |
| Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | NCT00157274 | Mycosis Fungoid... Sezary Syndrome | alemtuzumab | 18 Years - 75 Years | Latin American Cooperative Onco-Haematology Group - Peru | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) | NCT03821610 | Acute Lymphobla... | Fludarabine Melphalan Alemtuzumab Cyclophosphamid... Mesna Total Body Irra... | 40 Years - 70 Years | University of Birmingham | |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00230282 | Leukemia B-cell Leukemia Chronic Leukemi... Chronic Lymphoc... | Alemtuzumab Fludarabine Cytoxan | 18 Years - | Stanford University | |
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00143065 | Lymphoma, Small... Lymphocytic Leu... | Fludarabine Rituximab Alemtuzumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | NCT00061048 | Acute T-Cell Le... | Alemtuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00328198 | B-Cell Chronic ... | Alemtuzumab Alemtuzumab | 18 Years - | Sanofi | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
| A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00923182 | Leukemia, Lymph... | alemtuzumab | 20 Years - 75 Years | Sanofi | |
| Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure | NCT00895739 | Nonmalignant Ne... | alemtuzumab cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | NCT01625351 | Ewing Sarcoma Gastrointestina... Germ Cell Tumor Hepatic Tumor Lymphoma Wilms Tumor Rhabdoid Tumor Clear Cell Carc... Renal Cell Carc... Melanoma Neuroblastoma Rhabdomyosarcom... Non-rhabdomyosa... | alemtuzumab fludarabine sirolimus Busulfan melphalan stem cells CliniMACS | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00983528 | Acute Lymphobla... | Alemtuzumab Clofarabine | 16 Years - | University of California, San Diego | |
| Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL | NCT00074282 | Leukemia | rituximab cyclophosphamid... pentostatin Alemtuzumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia | NCT01982175 | B-cell Chronic ... | Alemtuzumab | 18 Years - 75 Years | Shanghai Zhangjiang Biotechnology Limited Company | |
| Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | NCT01013961 | Chronic Lymphoc... | alemtuzumab rituximab | 65 Years - | Eastern Cooperative Oncology Group | |
| Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) | NCT01186640 | T-cell-prolymph... | Fludarabine, Mi... Alemtuzumab | 18 Years - | German CLL Study Group | |
| Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia | NCT00021151 | Leukemia | alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | NCT00637390 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Alemtuzumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia | NCT00336206 | B-Cell Chronic ... | Alemtuzumab | 18 Years - 75 Years | Tawam Hospital | |
| Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | NCT00046683 | B Cell Chronic ... | alemtuzumab | 18 Years - | Sanofi | |
| Cyclophosphamide and Alemtuzumab In Lymphoma | NCT03132584 | Non Hodgkin Lym... High-grade B-ce... Diffuse Large B... | Cyclophosphamid... Alemtuzumab | 18 Years - 75 Years | Dana-Farber Cancer Institute | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | NCT01269385 | B-cell Chronic ... Refractory Chro... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | alemtuzumab rituximab PGG beta-glucan flow cytometry laboratory biom... DNA analysis fluorescence in... polymerase chai... polymorphism an... mutation analys... | 18 Years - | Mayo Clinic | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | NCT00061945 | Acute Undiffere... B-cell Adult Ac... B-cell Childhoo... L1 Adult Acute ... L1 Childhood Ac... L2 Adult Acute ... L2 Childhood Ac... Philadelphia Ch... Philadelphia Ch... Philadelphia Ch... T-cell Adult Ac... T-cell Childhoo... Untreated Adult... Untreated Child... | allopurinol cyclophosphamid... daunorubicin hy... vincristine sul... dexamethasone asparaginase filgrastim imatinib mesyla... methotrexate cytarabine trimethoprim-su... mercaptopurine leucovorin calc... alemtuzumab acyclovir laboratory biom... pharmacological... | 15 Years - | National Cancer Institute (NCI) | |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | NCT03989466 | Recurrent T-Cel... T-Cell Prolymph... | Alemtuzumab Itacitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC | |
| Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | NCT00836043 | Chronic Lymphoc... | Alemtuzumab (Ma... | 18 Years - | Sanofi | |
| Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | NCT00089349 | Recurrent Child... | alemtuzumab methotrexate mercaptopurine | - 30 Years | National Cancer Institute (NCI) | |
| Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | NCT00505921 | Lymphoma | Campath-1H G-CSF GM-CSF BCNU Stem Cell Trans... Preparative Reg... Cytarabine Etoposide Melphalan Campath Fludarabine Cyclophosphamid... Low dose total ... | - 70 Years | M.D. Anderson Cancer Center | |
| Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) | NCT01186640 | T-cell-prolymph... | Fludarabine, Mi... Alemtuzumab | 18 Years - | German CLL Study Group | |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | NCT01361711 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | alemtuzumab ofatumumab biopsy | 18 Years - | Northwestern University | |
| The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL | NCT00441025 | Peripheral T-Ce... | Alemtuzumab | 15 Years - 65 Years | Mahidol University | |
| Alemtuzumab and Pentostatin In T-cell Neoplasms | NCT00453193 | Lymphoma Leukemia | Pentostatin Alemtuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia | NCT00086775 | Leukemia | alemtuzumab rituximab fludarabine pho... | 18 Years - | National Cancer Institute (NCI) | |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | NCT00943592 | Advanced Hemato... Leukemia Preleukemia | Clofarabine Melphalan Campath Stem Cell Trans... | 18 Years - 75 Years | University of Chicago | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | NCT00077961 | Non-Hodgkin's L... | CAMPATH (alemtu... | 18 Years - | Sanofi | |
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00143065 | Lymphoma, Small... Lymphocytic Leu... | Fludarabine Rituximab Alemtuzumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia | NCT00773149 | Acute Lymphocyt... | Alemtuzumab (CA... | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| CFAR Study in Patients With Chronic Lymphocytic Leukemia | NCT00525603 | Leukemia Chronic Lymphoc... | Cyclophosphamid... Fludarabine Alemtuzumab Rituximab | - 69 Years | M.D. Anderson Cancer Center | |
| R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia | NCT00504491 | Chronic Lymphoc... Patients Resist... Patients Relaps... | Rituximab-CHOP-... | 18 Years - 70 Years | CABYC | |
| Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | NCT00051701 | Non-Hodgkins Ly... | alemtuzumab | 18 Years - | Sanofi | |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia | NCT01982175 | B-cell Chronic ... | Alemtuzumab | 18 Years - 75 Years | Shanghai Zhangjiang Biotechnology Limited Company | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | NCT00720447 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cytarabine etoposide melphalan allogeneic bone... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | NCT00951457 | Leukemia, Lymph... | Bendamustine Alemtuzumab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia | NCT00081068 | Lymphoma | alemtuzumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine | NCT00274976 | Leukemia | alemtuzumab | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | NCT00051701 | Non-Hodgkins Ly... | alemtuzumab | 18 Years - | Sanofi | |
| CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | NCT00323323 | Non-Hodgkin's L... | CHOP Alemtuzumab Plasma Samples | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC | |
| The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) | NCT00930605 | Peripheral T-ce... | CHOP regimen al... Alemtuzumab | 15 Years - 65 Years | King Chulalongkorn Memorial Hospital | |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders | NCT00553098 | Immunodeficienc... Non-Cancer Diag... | Alemtuzumab Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... | - 54 Years | Fred Hutchinson Cancer Center | |
| Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | NCT00281983 | Chronic Lymphoc... | alemtuzumab anti-thymocyte ... filgrastim rituximab therapeutic all... busulfan cyclophosphamid... cyclosporine fludarabine pho... methotrexate mycophenolate m... peripheral bloo... radiation thera... | 18 Years - 65 Years | German CLL Study Group | |
| Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00006390 | Leukemia | alemtuzumab filgrastim cyclophosphamid... peripheral bloo... radiation thera... | 18 Years - 65 Years | Eastern Cooperative Oncology Group | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
